Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
According to the company, registration is required for dial-in details, the live webcast link is provided, and an archived webcast will be available for at least 30 days in Investors on www.acumenpharm.com.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
In the Mar 20 session, ABOS declined 8.56%, reflecting a notable negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Scientific data update | Positive | -7.5% | New AD/PD 2026 preclinical and biomarker data on brain delivery and antibodies. |
| Mar 16 | Financing / placement | Neutral | +1.5% | $35.75M private placement at $3.30 per share to fund EBD program. |
| Mar 10 | Conference participation | Neutral | +0.3% | Announcement of fireside chat at Stifel 2026 Virtual CNS Forum. |
| Mar 03 | Conference preview | Positive | +0.3% | Plan to present EBD, biomarkers, and AβO antibodies at AD/PD 2026. |
| Dec 02 | Clinical trial update | Positive | -7.9% | CTAD data on enhanced brain delivery and ALTITUDE‑AD recruitment metrics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive scientific and clinical updates have twice been followed by notable single-day declines, while financing and conference-related news have seen relatively muted or modestly positive reactions.
Over the past months, Acumen has emphasized Alzheimer’s R&D and capital raising. In Dec 2025, CTAD data on Enhanced Brain Delivery™ and Phase 2 ALTITUDE-AD recruitment coincided with a -7.89% move. AD/PD 2026 data on March 17 saw a further -7.49%. By contrast, the $35.75M private placement on Mar 16, 2026 and multiple conference participation announcements saw small positive or flat reactions, suggesting mixed sensitivity to news type.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
ICR Healthcare
AcumenPR@icrhealthcare.com
